Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | NMT1 | P30419 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20569447 | 0.84 | TDP1 (0.45) | SMN1; SMN2TDP1 | |
| SCHEMBL20572275 | 0.81 | KCNH2 (0.50) | SMN1; SMN2NMT1 | |
| SCHEMBL9341301 | 0.80 | TDP1 (0.58) | SMN1; SMN2TDP1 | |
| SCHEMBL20570528 | 0.79 | FFAR1 (0.42) | — | |
| SCHEMBL8541622 | 0.78 | GRIN2B (0.52) | SIGMAR1 | |
| SCHEMBL25067265 | 0.78 | TLR8 (0.59) | SMN1; SMN2NMT1TDP1 | |
| SCHEMBL27507350 | 0.78 | CYP3A4 (0.43) | SIGMAR1TDP1 | |
| SCHEMBL24127752 | 0.77 | SMN1; SMN2 (0.49) | SMN1; SMN2TDP1 | |
| SCHEMBL10419080 | 0.77 | SMN1; SMN2 (0.51) | SMN1; SMN2TDP1 | |
| SCHEMBL5824074 | 0.76 | TLR8 (0.57) | SMN1; SMN2NMT1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227466-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227466-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | KRAS, G3BP1, NRAS | SMN1; SMN2 3947/4885SIGMAR1 4803/4885NMT1 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.